Express Mail Label No.: EL862267408\(\overline{1}\)5 Date of Deposit: December 3, 2001

Date of Deposit: December 3, 2001 Attorney Docket No.: 21402-018 (Cura-318)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Rastelli and Smithson

SERIAL NO.:

09/865,812

FILING DATE:

May 25, 2001

For:

Method of Detecting Inflammatory Lung Disorders

Box IDS

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. This Information Disclosure Statement is being been filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is believed required. A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 21402-018 (Cura-318).

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Cynthia A. Kozakiewicz, Reg.No. 42,764

Attorneys for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS

GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: December 3, 2001

Express Mail No.: EL862267408uS Date of D posit: December 3, 2001

Please type a plus sign (+) in this box

r		
l	+	

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO	Application Number	09/865,812
	Filing Date	05/25/01
INFORMATION DISCLOSURE	First Named Inventor	Rastelli
STATEMENT BY APPLICANT	Group Art Unit	1632
	Examiner Name	Not Yet Assigned
(use as many sheets as necessary)	Attorney Docket Number	21402-018 (Cura-318)

		全全电台中 人名斯坦滕		U.S. PATENT DOCUMENTS			
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,871,697	02/16/99	Rothberg et al.			10/24/95

************	***********	PPENERALINARENE (PENERALINAREN ERRENEE ERRENEE (PENERALINA)	FÖREIGN PATENT DOCUMENTS	**************************************	CAPTURED AND CONTRACTOR OF THE PROPERTY OF THE
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1		_		

		OTHER PRIOR ART # NON PATENT; LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Capecchi, M. (1989). "Altering the genome by homologous recombination." Science 244: 1288-1292.
	C2	Heinzel, R. et al. (1986). "Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus." <i>Eur. J. Biochem.</i> 160(1): 61-67. GenBank Accession Number: X04470
	СЗ	Shimkets, R. et al. (1999). "Gene expression analysis by transcript profiling coupled to a gene database query." <i>Nat Biotechnol</i> <u>17</u> (8): 798-803.

* A copy of	this reference is not provided as it v	vas previously cited by or submitted to the office in a prior application,
Serial No.	, filed	, and relied upon for an earlier filing date under
35 U.S.C. §	120 (continuation, continuation-in-p	art, and divisional applications).

Examiner Signature	Date Considered	
1	1	l <u>.</u>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1601217v1

Express Mail Label No.: EV109727221US

Date of Deposit: April 30, 2003 Attorney Docket No.: 21402-018 (Cura-318)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Rastelli and Smithson

SERIAL NUMBER:

09/865,812

EXAMINER:

Lacourciere, Karen A.

FILING DATE:

May 25, 2001

ART UNIT:

1635

FOR:

METHOD OF DETECTING INFLAMMATORY LUNG DISORDERS

Box IDS

Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of a Partial International Search Report for corresponding application PCT/US01/17211 on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Rastelli and Smithson U.S.S.N. 09/865,812

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21402-018 (Cura-318).

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS

GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: April 30, 2003

TRA 1786030v1

1635

Lacourciere, Karen A.

21402-018 (Cura-318)

Express Mail N .: EV109727221US Dat of Deposit: April 30, 2003

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Please type a plus sign (+) in this box +

Γ	Modified Form 1449/PTO	Application Number	09/865,812
		Filing Date	05/25/01
l	INFORMATION DISCLOSURE	First Named Inventor	Rastelli

Exam			1			T	T
	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A2	5,633,227	05/27/1997	Muller, et al.			09/12/1994

Group Art Unit

Examiner Name

Attorney Docket Number

				FOREIGN PATENT DOCUMENTS		
Exam Initials	Cite No.	Foreig Office	gn Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	В					

		OF SECONDER PRIOR ART NON PATENT LITERATURE DOCUMENTS:
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C4	Abe, et al. (1997). "Bacteria pneumonia causes augmented expression of the secretory leukoprotease inhibitor gene in the murine lung." American Journal of Respiratory and Association. 156: 1235-1240.
	C5	Bingle, et al. (1996). "Secretory leukoprotease inhibitor: partnering alpha1-proteinsase inhibitor to combat pulmonary inflammation." Thorax. 51(12): 1273-1274.
	C6	EMBASE Online Accesion No.: P03973 . 10/23/1986.
	ıC7	EMBASE Online Accesion No.: X04470. 03/09/1987.
	C8	Fath, et al. (1998). "Interaction of secretory leukocyte protease inhibitor with heparin inhibits protease involved in asthma." Journal of Biological Chemistry. 273(22): 13563-13569.
	C9	Gipson, et al. (1999). "Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury." Journal of Immunology. 162(6): 3653-3662.
	C10	Kida, et al. (1992). "Serum secretory leukoprotease inhibitor levels to diagnose pneumonia in the elderly." The American Review of Respiratory Disease. 146(6): 1426-1429.
	C11	Thompson, et al. (1986). "Isolation properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase." Proceedings of The National Academy of Sciences of USA. 83: 6692-6696.
	C12	Van Wetering, et al. (2000). "Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins." American Journal of Physiology. 278(1): L51-L58.
	C13	Vogelmeier, et al. (1996). "Use of secretory leukoprotease inhibitor to augment lung antineutriphil elastase activity." Chest. 110(6): 261S-266S.
	C14	Wright, et al. (1999). "Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma." The Journal of Pharmacology and Exerimental Therapeutics. 289(2): 1007-1014.
	C15	Partial International Search Report for PCT/US01/17211. Mailed February 26, 2003.

Express Mail N .: EV109727221US Dat of Dep sit: April 30, 2003

Page 2 of 2

Serial No	is reference is not provided as it was previous, filed	, and relied upon for an earli	
Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1786036v1